Sandy Hook, CT, United States of America

Rogelio Perez Frutos

This inventor holds 17 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharmaceuticals, Inc.. Active years: 2002-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Rogelio Perez Frutos. Retrieved from https://idiyas.com/inventor/rogelio-perez-frutos

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 3)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 96(Granted Patents)

Company Filing History:

12 out of 1,562

Boehringer Ingelheim International Gmbh

patents

6 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

where one patent can have more than one assignee

Years Active: 2002-2020

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10745411 - Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma (2020-08-18),

2. 9802954 - Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma (2017-10-31),

3. 9150586 - Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma (2015-10-06),

4. 8653282 - Preparation of dihydrothieno [3,2-D] pyrimidines and intermediates used therein (2014-02-18),

5. 8609670 - Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma (2013-12-17),

6. 8471010 - [object Object] (2013-06-25),

7. 8101765 - Process for preparing acyclic HCV protease inhibitors (2012-01-24),

8. 8017771 - Process for preparing acyclic HCV protease inhibitors (2011-09-13),

9. 7858804 - Process for making cytokine inhibiting compounds containing 4- and 5-imidazolyl rings and the intermediates thereof (2010-12-28),

10. 7514557 - Process for preparing acyclic HCV protease inhibitors (2009-04-07),

11. 7470795 - Synthesis of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid amides (2008-12-30),

12. 7148347 - Process for preparing macrocyclic compounds (2006-12-12),

13. 6458986 - Intermediate for (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-&agr;]imidazol-2-one (2002-10-01),

14. 6441183 - Intermediate for (R)-3-(4-Bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one (2002-08-27),

15. 6437148 - Intermediates for (R)-3(4-bromobenzyl)-1-(3,5-dichlorophenyl)-5-iodo-3-methyl-1-H-imidazo[1,2-a]imidazol-2-one (2002-08-20),

Title: Rogelio Perez Frutos: Pioneering Inventor from Sandy Hook

Introduction: Rogelio Perez Frutos is a distinguished inventor hailing from Sandy Hook, CT, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Rogelio Perez Frutos holds several patents in the areas of renewable energy, artificial intelligence, and sustainable agriculture, showcasing his versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Rogelio Perez Frutos has worked with leading tech companies to develop cutting-edge solutions that have revolutionized various industries. His innovative spirit and dedication to progress have earned him a reputation as a visionary in the field of invention.

Collaborations: Throughout his career, Rogelio Perez Frutos has collaborated with top researchers, engineers, and scientists to bring his ideas to life. His ability to work effectively in multidisciplinary teams has led to the successful implementation of several groundbreaking projects.

Conclusion: Rogelio Perez Frutos continues to push the boundaries of innovation, inspiring the next generation of inventors to think boldly and creatively. His passion for creating a better future through technology sets him apart as a true pioneer in the world of invention.

Profile summary based on public USPTO records.